Novo Nordisk's weight loss drug Wegovy receives approval from the European Union, reducing the risk of major heart disease by 20%
I'm PortAI, I can summarize articles.
According to an announcement from Novo Nordisk, the European Medicines Agency (EMA) supports the company's use of the weight-loss drug Wegovy to reduce the risk of stroke and heart disease. The EMA's Committee for Medicinal Products for Human Use believes that this decision is based on extensive research data supported by Novo Nordisk, which found that Wegovy can reduce the risk of major heart diseases by one-fifth. On Thursday, Novo Nordisk's US stock price fell nearly 4% at one point, but the decline was halved later
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments